Free tool
FAERS Monitor: Avita
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020404 or its brand name (Avita, Tretinoin). Reports on generic versions are filed under their own applications.
Reports
6,524
Serious
4,112
63% of reports
Hospitalization
1,416
Death reported
851
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use876
- drug ineffective727
- pain489
- product use in unapproved indication483
- vomiting450
- paraesthesia372
- abdominal pain upper368
- rash361
- nausea350
- diarrhoea347
- maternal exposure during pregnancy338
- headache335
- taste disorder332
- drug intolerance327
- gastrooesophageal reflux disease327
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 37 |
| 2005 | 31 |
| 2006 | 24 |
| 2007 | 39 |
| 2008 | 114 |
| 2009 | 72 |
| 2010 | 78 |
| 2011 | 89 |
| 2012 | 153 |
| 2013 | 100 |
| 2014 | 147 |
| 2015 | 223 |
| 2016 | 342 |
| 2017 | 343 |
| 2018 | 460 |
| 2019 | 350 |
| 2020 | 374 |
| 2021 | 426 |
| 2022 | 510 |
| 2023 | 568 |
| 2024 | 674 |
| 2025 | 809 |
| 2026 | 561 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,635 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| taste disorderSignal | 332 | 53.6 | 48.2 | 16,828 |
| gastrooesophageal reflux diseaseSignal | 327 | 13.1 | 11.8 | 3,656 |
| maternal exposure during pregnancySignal | 338 | 12.3 | 11.1 | 3,489 |
| drug intoleranceSignal | 327 | 10.9 | 9.8 | 2,949 |
| paraesthesiaSignal | 372 | 7.6 | 6.9 | 2,151 |
| product use in unapproved indicationSignal | 483 | 6.3 | 5.8 | 2,166 |
| abdominal pain upperSignal | 368 | 5.8 | 5.2 | 1,458 |
| off label useSignal | 876 | 3.2 | 3.0 | 1,401 |
| vomitingSignal | 450 | 3.1 | 2.8 | 647 |
| rashSignal | 361 | 2.7 | 2.4 | 383 |
| painSignal | 489 | 2.6 | 2.4 | 480 |
| drug ineffective | 727 | 1.8 | 1.7 | 264 |
| diarrhoea | 347 | 1.7 | 1.6 | 110 |
| headache | 335 | 1.7 | 1.6 | 104 |
| nausea | 350 | 1.4 | 1.3 | 46 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.